Theoretically, targeting downstream signaling pathways of TGF‐β and Ang II, such as ERK1/2, mTOR, PI3/Akt, P38/MAPK, and Rho kinase signaling pathways, could attenuate the pathogenesis of AAA. Here, MAPK3 is linked to triple-A syndrome.